JP6431477B2 - インフルエンザの中和のための薬剤 - Google Patents

インフルエンザの中和のための薬剤

Info

Publication number
JP6431477B2
JP6431477B2 JP2015511463A JP2015511463A JP6431477B2 JP 6431477 B2 JP6431477 B2 JP 6431477B2 JP 2015511463 A JP2015511463 A JP 2015511463A JP 2015511463 A JP2015511463 A JP 2015511463A JP 6431477 B2 JP6431477 B2 JP 6431477B2
Authority
JP
Japan
Prior art keywords
antibody
influenza
binding
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015511463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517492A (ja
JP2015517492A5 (enExample
Inventor
エス． ラグラム，
エス． ラグラム，
ビスワナサン サシセカラン，
ビスワナサン サシセカラン，
ベンカタラマナン サンダララジャン，
ベンカタラマナン サンダララジャン，
サシセカラン，　ラム
ラム サシセカラン，
ビジャ スブラマニアン，
ビジャ スブラマニアン，
カナン サラカラマン，
カナン サラカラマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2015517492A publication Critical patent/JP2015517492A/ja
Publication of JP2015517492A5 publication Critical patent/JP2015517492A5/ja
Application granted granted Critical
Publication of JP6431477B2 publication Critical patent/JP6431477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015511463A 2012-05-10 2013-03-14 インフルエンザの中和のための薬剤 Active JP6431477B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645453P 2012-05-10 2012-05-10
US61/645,453 2012-05-10
PCT/US2013/031704 WO2013169377A1 (en) 2012-05-10 2013-03-14 Agents for influenza neutralization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018070701A Division JP2018118991A (ja) 2012-05-10 2018-04-02 インフルエンザの中和のための薬剤

Publications (3)

Publication Number Publication Date
JP2015517492A JP2015517492A (ja) 2015-06-22
JP2015517492A5 JP2015517492A5 (enExample) 2016-05-12
JP6431477B2 true JP6431477B2 (ja) 2018-12-05

Family

ID=49548780

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015511463A Active JP6431477B2 (ja) 2012-05-10 2013-03-14 インフルエンザの中和のための薬剤
JP2018070701A Pending JP2018118991A (ja) 2012-05-10 2018-04-02 インフルエンザの中和のための薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018070701A Pending JP2018118991A (ja) 2012-05-10 2018-04-02 インフルエンザの中和のための薬剤

Country Status (14)

Country Link
US (4) US9683030B2 (enExample)
EP (2) EP3492101A3 (enExample)
JP (2) JP6431477B2 (enExample)
KR (1) KR102122618B1 (enExample)
CN (2) CN109265541A (enExample)
AU (2) AU2013260123A1 (enExample)
BR (1) BR112014027991A2 (enExample)
CA (1) CA2871160C (enExample)
CL (1) CL2014003052A1 (enExample)
HK (1) HK1207970A1 (enExample)
IL (1) IL235237A0 (enExample)
MX (1) MX378749B (enExample)
SG (2) SG11201406769RA (enExample)
WO (1) WO2013169377A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9683030B2 (en) 2012-05-10 2017-06-20 Massachusetts Institute Of Technology Agents for influenza neutralization
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CA2975655C (en) 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
CA2985402A1 (en) * 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
KR101887876B1 (ko) 2016-08-18 2018-08-13 한국과학기술연구원 H5형 조류독감 바이러스에 특이적으로 결합하는 핵산 압타머 및 이를 이용하는 h5형 조류독감 바이러스의 검출방법
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2023506156A (ja) * 2019-12-11 2023-02-15 ビステラ， インコーポレイテッド インフルエンザを処置または予防するための組成物および方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL23522C (enExample) 1927-03-23
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
JPH06247995A (ja) 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
JP3584990B2 (ja) * 1994-05-09 2004-11-04 タカラバイオ株式会社 抗ヒトインフルエンザウイルス抗体
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
AU3328900A (en) 1999-03-31 2000-10-23 Otsuka Pharmaceutical Co., Ltd. Influenza virus hemagglutinin-binding peptides
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
EP1489101A1 (en) 2002-03-04 2004-12-22 Japan Science and Technology Agency Novel branched sialo-sugar molecules and antiviral agents using the same
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
BR0313650A (pt) 2002-08-20 2007-08-14 Genitrix Llc composição, vetor de expressão, composição de vacina e uso
US20080292658A1 (en) 2004-11-11 2008-11-27 Emmie De Wit Defective Influenza Virus Particles
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CA2590590C (en) 2004-12-22 2016-04-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
CN101553502A (zh) 2006-08-14 2009-10-07 麻省理工学院 血球凝集素多肽和其相关试剂和方法
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CA2660128A1 (en) 2006-08-14 2008-02-21 Massachusetts Institute Of Technology Glycan data mining system
EA017957B1 (ru) * 2007-06-25 2013-04-30 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Композиции и способы, ингибирующие грипп
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
WO2009079259A2 (en) * 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009089121A2 (en) 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
KR20110049802A (ko) 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
AU2011210840B2 (en) * 2010-01-27 2014-12-11 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
SG189236A1 (en) 2010-10-04 2013-05-31 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9683030B2 (en) 2012-05-10 2017-06-20 Massachusetts Institute Of Technology Agents for influenza neutralization
JP6247995B2 (ja) 2014-04-22 2017-12-13 東京エレクトロン株式会社 接合方法、プログラム、コンピュータ記憶媒体、接合装置及び接合システム

Also Published As

Publication number Publication date
CN104507500A (zh) 2015-04-08
US20190062407A1 (en) 2019-02-28
SG11201406769RA (en) 2014-11-27
EP3492101A2 (en) 2019-06-05
JP2015517492A (ja) 2015-06-22
AU2013260123A1 (en) 2014-11-13
US20170306003A1 (en) 2017-10-26
MX2014013678A (es) 2015-02-04
IL235237A0 (en) 2014-12-31
US9683030B2 (en) 2017-06-20
CA2871160A1 (en) 2013-11-14
AU2018202468B2 (en) 2020-04-16
CL2014003052A1 (es) 2015-06-26
JP2018118991A (ja) 2018-08-02
KR102122618B1 (ko) 2020-06-29
BR112014027991A2 (pt) 2017-07-18
US10538578B2 (en) 2020-01-21
WO2013169377A1 (en) 2013-11-14
EP2846833A1 (en) 2015-03-18
US10947300B2 (en) 2021-03-16
MX378749B (es) 2025-03-10
CA2871160C (en) 2023-03-14
HK1207970A1 (en) 2016-02-19
SG10201807059QA (en) 2018-09-27
AU2018202468A1 (en) 2018-04-26
KR20150008180A (ko) 2015-01-21
EP3492101A3 (en) 2019-10-23
CN109265541A (zh) 2019-01-25
US20200123234A1 (en) 2020-04-23
US9982037B2 (en) 2018-05-29
EP2846833A4 (en) 2016-01-06
US20130302348A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
JP6431477B2 (ja) インフルエンザの中和のための薬剤
JP6605643B2 (ja) 抗デングウイルス抗体およびその使用
US11421018B2 (en) Full spectrum anti-dengue antibody
JP6210685B2 (ja) 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
US10526375B2 (en) Human Adaptation of H7 HA
HK1233537A1 (en) Novel full spectrum anti-dengue antibody
HK1233537B (en) Novel full spectrum anti-dengue antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181102

R150 Certificate of patent or registration of utility model

Ref document number: 6431477

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250